Ibopamine

14,000,000 Leading Edge Experts on the ideXlab platform

Scan Science and Technology

Contact Leading Edge Experts & Companies

Scan Science and Technology

Contact Leading Edge Experts & Companies

The Experts below are selected from a list of 381 Experts worldwide ranked by ideXlab platform

Marcos Pereira De ,Ávila - One of the best experts on this subject based on the ideXlab platform.

  • Comparação entre o teste de ibopamina a 1% e a 2% no glaucoma primário de ângulo aberto: sensibilidade, especificidade e tolerabilidade
    'FapUNIFESP (SciELO)', 2015
    Co-Authors: Magacho Leopoldo, Costa, Marcelus Layguel, Dessimoni André, Marcos Pereira De ,Ávila
    Abstract:

    PURPOSE: To compare intraocular pressure (IOP) rise in normal individuals and primary open-angle glaucoma patients and the safety and efficacy of Ibopamine eye drops in different concentrations as a provocative test for glaucoma. METHODS: Glaucoma patients underwent (same eye) the Ibopamine provocative test with two concentrations, 1% and 2%, in a random sequence at least 3 weeks apart, but not more than 3 months. The normal individuals were randomly submitted to one of the concentrations of Ibopamine (1% and 2%). The test was considered positive if there was an IOP rise greater than 3 or 4 mmHg at 30 or 45 minutes to test which subset of the test has the best sensitivity (Se)/specificity (Sp). RESULTS: There was no statistically significant difference in any of the IOP measurements, comparing 1% with 2% Ibopamine. The IOP was significantly higher at 30 and 45 minutes with both concentrations (p3 mmHg, 45 minutos após o teste com a ibopamina a 2% (área abaixo da curva ROC: 0,864, Se: 84,6%; Es: 73,3%). Todos os pacientes referiram leve ardência à instilação da ibopamina. CONCLUSÃO: Sugere-se a utilização da ibopamina a 2% como teste provocativo para o glaucoma. Como ambas as concentrações apresentaram capacidade similar em elevar a Pio, a Ibopamina a 1% (menor concentração da droga) pode ser utilizada por períodos prolongados, como na hipotonia ocular.69569

  • 2% Ibopamine vs. water-drinking test as a provocative test for glaucoma
    Conselho Brasileiro de Oftalmologia, 2015
    Co-Authors: Magacho Leopoldo, Reis Ricardo, Pigini, Mara Agi, Marcos Pereira De ,Ávila
    Abstract:

    PURPOSE: To compare the 2% Ibopamine provocative test with the water drinking test as a provocative test for glaucoma. METHODS: Primary open-angle glaucoma patients and normal individuals were selected from CEROF-Universidade Federal de Goiânia UFG, and underwent the 2% Ibopamine provocative test and the water drinking test in a randomized fashion, at least 1 week apart. Intraocular pressure (IOP) before and after both tests, Bland-Altman graph, sensitivity and specificity (as mesured by ROC curves) were obtained for both methods. RESULTS: Forty-seven eyes from 25 patients were included (27 eyes from 15 glaucoma patients and 20 eyes from 10 normal individuals), with a mean age of 54.2 ± 12.7 years. The mean MD of glaucoma patients was -2.8 ± 2.11 dB. There was no statistically difference in the baseline IOP (p=0.8) comparing glaucoma patients, but positive after the provocative tests (p=0.03), and in the IOP variation (4.4 ± 1.3 mmHg for Ibopamine and 3.2 ± 2.2 mmHg for water drinking test, p=0.01). There was no difference in all studied parameters for normal individuals. The Bland-Altman graph showed high dispersion comparing both methods. The areas under the ROC curve were 0.987 for the Ibopamine provocative test, and 0.807 for the water-drinking test. CONCLUSION: In this selected subgroup of glaucoma patients with early visual field defect, the Ibopamine provocative test has shown better sensitivity/specificity than the water drinking test.OBJETIVO: Comparar o teste da ibopamina 2% com o teste de sobrecarga hídrica como testes provocativos para glaucoma. MÉTODOS: Pacientes com glaucoma primário de ângulo aberto, e indivíduos normais foram selecionados do CEROF-Universidade Federal de Goiás - UFG, e submetidos, de forma randomizada, e com intervalo mínimo de 1 semana, aos testes provocativos da ibopamina 2%, e sobrecarga hídrica. A pressão intra-ocular (Pio) antes e após os testes, confrontação entre os métodos (gráfico de Bland-Altman) além da melhor relação sensibilidade/especificidade (realizados por meio de curvas ROC) foram obtidos. RESULTADOS: Foram incluídos 47 olhos de 25 pacientes (27 olhos de 15 pacientes com glaucoma e 20 olhos de 10 pacientes normais), com idade média de 54,2 ± 12,7 anos. O MD médio dos pacientes com glaucoma foi de -2,8 ± 2,11 dB. Nos pacientes com glaucoma, não houve diferença estatisticamente significativa na Pio basal (p=0,8), ao passo que se notou diferença na Pio após os testes provocativos (p=0,03), e na variação da Pio após os testes (4,4 ± 1,3 mmHg para ibopamina e 3,2 ± 2,2 mmHg para ingestão hídrica, p=0,01). Nos pacientes normais, não houve diferença estatisticamente significativa entre os grupos para todos os parâmetros avaliados. O gráfico de Bland-Altman mostrou grande dispersão dos resultados. Finalmente, obteve-se áreas abaixo das curvas ROC de 0,987 para o teste da ibopamina e 0,807 para a ingestão hídrica. CONCLUSÃO: O teste provocativo da ibopamina apresentou melhor relação sensibilidade/especificidade que o teste de ingestão hídrica nesse subgrupo selecionado de pacientes com glaucoma com dano perimétrico inicial

  • Comparação entre o teste de ibopamina a 1% e a 2% no glaucoma primário de ângulo aberto: sensibilidade, especificidade e tolerabilidade
    Conselho Brasileiro de Oftalmologia, 2014
    Co-Authors: Magacho Leopoldo, Costa, Marcelus Layguel, Dessimoni André, Marcos Pereira De ,Ávila
    Abstract:

    PURPOSE: To compare intraocular pressure (IOP) rise in normal individuals and primary open-angle glaucoma patients and the safety and efficacy of Ibopamine eye drops in different concentrations as a provocative test for glaucoma. METHODS: Glaucoma patients underwent (same eye) the Ibopamine provocative test with two concentrations, 1% and 2%, in a random sequence at least 3 weeks apart, but not more than 3 months. The normal individuals were randomly submitted to one of the concentrations of Ibopamine (1% and 2%). The test was considered positive if there was an IOP rise greater than 3 or 4 mmHg at 30 or 45 minutes to test which subset of the test has the best sensitivity (Se)/specificity (Sp). RESULTS: There was no statistically significant difference in any of the IOP measurements, comparing 1% with 2% Ibopamine. The IOP was significantly higher at 30 and 45 minutes with both concentrations (p

  • Efeitos da ibopamina 2% tópica nos resultados da campimetria visual computadorizada Effects of 2% Ibopamine eye drops on computerized visual field results
    Conselho Brasileiro de Oftalmologia, 2009
    Co-Authors: Mara Agi Pigini, Marcos Pereira De ,Ávila, Leopoldo Magacho
    Abstract:

    OBJETIVO: Avaliar os efeitos do uso do colírio de ibopamina a 2% nos resultados da campimetria visual computadorizada em indivíduos normais. MÉTODOS: Voluntários oriundos do CEROF-UFG, sem alterações ao exame oftalmológico que pudessem afetar o campo visual foram selecionados. Os indivíduos foram submetidos a exame de perimetria computadorizada SITA-standard 24-2 antes e após dilatação com o colírio de ibopamina a 2% ou ciclopentolato, com intervalo mínimo de 3 dias entre si e em ordem aleatória. Índices globais e número de pontos alterados foram comparados entre os grupos. RESULTADOS: Foram avaliados 30 olhos de 30 indivíduos normais. Não houve diferença estatisticamente significativa entre o "mean deviation" (MD) nos pacientes não dilatados e nos mesmos após a instilação da ibopamina (MD: -1,05 ± 0,26 dB vs. -1,47 ± 0,20 dB, P=0,08), o que ocorreu após cicloplegia (MD: -3,19 ± 0,29 dB), P

  • Ibopamina 2% vs. sobrecarga hídrica como teste provocativo para glaucoma 2% Ibopamine vs. water-drinking test as a provocative test for glaucoma
    Conselho Brasileiro de Oftalmologia, 2008
    Co-Authors: Leopoldo Magacho, Ricardo Reis, Mara Agi Pigini, Marcos Pereira De ,Ávila
    Abstract:

    OBJETIVO: Comparar o teste da ibopamina 2% com o teste de sobrecarga hídrica como testes provocativos para glaucoma. MÉTODOS: Pacientes com glaucoma primário de ângulo aberto, e indivíduos normais foram selecionados do CEROF-Universidade Federal de Goiás - UFG, e submetidos, de forma randomizada, e com intervalo mínimo de 1 semana, aos testes provocativos da ibopamina 2%, e sobrecarga hídrica. A pressão intra-ocular (Pio) antes e após os testes, confrontação entre os métodos (gráfico de Bland-Altman) além da melhor relação sensibilidade/especificidade (realizados por meio de curvas ROC) foram obtidos. RESULTADOS: Foram incluídos 47 olhos de 25 pacientes (27 olhos de 15 pacientes com glaucoma e 20 olhos de 10 pacientes normais), com idade média de 54,2 ± 12,7 anos. O MD médio dos pacientes com glaucoma foi de -2,8 ± 2,11 dB. Nos pacientes com glaucoma, não houve diferença estatisticamente significativa na Pio basal (p=0,8), ao passo que se notou diferença na Pio após os testes provocativos (p=0,03), e na variação da Pio após os testes (4,4 ± 1,3 mmHg para ibopamina e 3,2 ± 2,2 mmHg para ingestão hídrica, p=0,01). Nos pacientes normais, não houve diferença estatisticamente significativa entre os grupos para todos os parâmetros avaliados. O gráfico de Bland-Altman mostrou grande dispersão dos resultados. Finalmente, obteve-se áreas abaixo das curvas ROC de 0,987 para o teste da ibopamina e 0,807 para a ingestão hídrica. CONCLUSÃO: O teste provocativo da ibopamina apresentou melhor relação sensibilidade/especificidade que o teste de ingestão hídrica nesse subgrupo selecionado de pacientes com glaucoma com dano perimétrico inicial.PURPOSE: To compare the 2% Ibopamine provocative test with the water drinking test as a provocative test for glaucoma. METHODS: Primary open-angle glaucoma patients and normal individuals were selected from CEROF-Universidade Federal de Goiânia UFG, and underwent the 2% Ibopamine provocative test and the water drinking test in a randomized fashion, at least 1 week apart. Intraocular pressure (IOP) before and after both tests, Bland-Altman graph, sensitivity and specificity (as mesured by ROC curves) were obtained for both methods. RESULTS: Forty-seven eyes from 25 patients were included (27 eyes from 15 glaucoma patients and 20 eyes from 10 normal individuals), with a mean age of 54.2 ± 12.7 years. The mean MD of glaucoma patients was -2.8 ± 2.11 dB. There was no statistically difference in the baseline IOP (p=0.8) comparing glaucoma patients, but positive after the provocative tests (p=0.03), and in the IOP variation (4.4 ± 1.3 mmHg for Ibopamine and 3.2 ± 2.2 mmHg for water drinking test, p=0.01). There was no difference in all studied parameters for normal individuals. The Bland-Altman graph showed high dispersion comparing both methods. The areas under the ROC curve were 0.987 for the Ibopamine provocative test, and 0.807 for the water-drinking test. CONCLUSION: In this selected subgroup of glaucoma patients with early visual field defect, the Ibopamine provocative test has shown better sensitivity/specificity than the water drinking test

Lie K. - One of the best experts on this subject based on the ideXlab platform.

  • Clinical and autonomic effects of Ibopamine as adjunct to angiotensin-converting enzyme inhibitors in chronic heart failure.
    'Elsevier BV', 1996
    Co-Authors: Szabó B. M., Van Veldhuisen D. J., Van Der Burgh P. H., Kruik J., Girbes A. R., Lie K.
    Abstract:

    BACKGROUND: The purpose of this study was to determine the additive value of Ibopamine in heart failure patients who are treated with angiotensin-converting enzyme inhibitors. Ibopamine exerts hemodynamic and neurohumoral effects, and is beneficial in mild heart failure; however, its additive value in more advanced disease in unclear. METHODS AND RESULTS: The study was a stand-alone, double-blind, randomized parallel group comparison of Ibopamine (100 mg 3 times daily) and placebo in 59 patients with New York Heart Association functional class III-IV heart failure. Patients were clinically stable on drug treatment, including an angiotensin-converting enzyme inhibitor, and they were randomized to Ibopamine (n = 29) or placebo (n = 30). Assessments were performed at baseline and after 3 months of treatment, and included measurement of peak oxygen consumption, plasma neurohormones, ambulatory arrhythmias, and heart rate variability. At baseline, the two groups were well matched, including age (mean, 63 years), left ventricular ejection fraction (0.23), and peak oxygen consumption (15.4 mL/min/kg). After 3 months, four patients had dropped out of the study because of progressive heart failure (Ibopamine, n = 1; placebo, n = 3; not significant) and two because of side effects (n = 1/1). Exercise time and peak oxygen consumption were not significantly affected (exercise time: Ibopamine, +54 [95% confidence interval, -12, 120] seconds; placebo, +19 [-42, 81] seconds; peak oxygen consumption: Ibopamine, +0.3 [-0.5, 1,2] mL/min/kg; placebo, +0.2 [-0.7, 1.0] mL/min/kg). Plasma neurohormones and ventricular arrhythmias during ambulatory monitoring were also unaffected. In contrast, heart rate variability parameters, in particular those associated with vagal tone (rMMSD, high-frequency power), significantly increased after 3 months on Ibopamine (P = .01 vs placebo). CONCLUSIONS: In this group of patients with clinically stable moderate to severe chronic heart failure, only a marginal and statistically nonsignificant effect on clinical parameters was observed after 3 months of treatment with Ibopamine. Heart rate variability parameters, however, were significantly affected by Ibopamine, despite the absence of an effect on plasma neurohormones

  • The effects of Ibopamine on glomerular filtration rate and plasma norepinephrine remain preserved during prolonged treatment in patients with congestive heart failure
    'Oxford University Press (OUP)', 1995
    Co-Authors: Lieverse A. G., Lie K., Meijer S, Girbes A. R.j., Smit A. J., Veldhuisen D. J.van, Zijlstra J. G., Reitsma W. D.
    Abstract:

    In acute studies Ibopamine, an aselective dopamine agonist, induces moderate increases of GFR and ERPF, and a fall in plasma norepinephrine levels in patients with congestive heart failure (CHF). We evaluated acute and chronic effects of Ibopamine on renal haemodynamics, sodium excretion, PRA, plasma aldosterone (ALD) and norepinephrine levels in an open controlled study in 10 patients aged (51-79 years) with mild CHF, NYHA class II-IIL All patients used digoxin andfrusemide. After a control study day, the second study day involved the administration of 100 mg Ibopamine. Subsequently the patients continued to take Ibopamine 100 mg three times daily for one month, at which time the chronic effects were measured on the third study day.Results: on the second study day ERPF rose from a baseline of 288 ± 32 to a mean of 308±32 ml. min -1 . 1.73 m -2 (P

  • Efficacy and safety of Ibopamine in congestive heart failure
    1994
    Co-Authors: Van Veldhuisen D. J., Girbes A. R.j., Lie K.
    Abstract:

    The oral dopamine agonist, Ibopamine, has beneficial cardiovascular, renal, and neuroendocrine effects. It is generally well tolerated by patient with congestive heart failure (CHF). Furthermore, the drug appears to be safe. Ibopamine may be used as an adjunct to therapy with digoxin, diuretics, and angiotensin-converting enzyme inhibitors for patients with advanced CHF, or as an alternative in those who do not tolerate these drugs. Research suggests that Ibopamine may, be used as first-line therapy for early CHF, and it may be given to patients who are dopamine-dependent

  • Neurohumoral and hemodynamic effects of Ibopamine in a rat model of chronic myocardial infarction and heart failure
    'Springer Science and Business Media LLC', 1994
    Co-Authors: Van Veldhuisen, Dirk J., Girbes, Armand R.j., De Graeff, Pieter A., Van Gilst, Wiek H., De Smet, Bart J.g.l., Scholtens Egbert, Buikema Hendrik, Wesseling Harry, Lie K.
    Abstract:

    There is increasing evidence that both neurohumoral and hemodynamic factors play a role in disease progression in chronic heart failure (CHF). To examine the influence of the oral dopamine agonist Ibopamine on these factors, we studied 20 rats with chronic myocardial infarction and CHF, and compared them with 20 normal rats. After 6 weeks, rats were randomly divided between control treatment (50%) or Ibopamine (50%) for 3 weeks. At the end of the study, plasma and tissue neurohumoral parameters, as well as hemodynamics, were determined. In infarcted rats, the elevated plasma norepinephrine (PNE) levels were reduced by Ibopamine (251±19 vs. 138±32 pg/ml; p

  • Effects of Ibopamine on the increase in plasma norepinephrine levels during exercise in congestive heart failure
    'Elsevier BV', 1993
    Co-Authors: Van Veldhuisen, Dirk J., Girbes, Armand R.j., De Graeff, Pieter A., Van Gilst, Wiek H., Van Den Broek, Stan A.j., Lie K.
    Abstract:

    Congestive heart failure (CHF) is accompanied by increased levels of plasma norepinephrine (PNE) at rest. During exercise, PNE levels increase rapidly in patients with CHF,1 causing skeletal vasoconstriction and muscle underperfusion. Because long-term sympathetic activation may be detrimental in patients with CHF,2 inhibition of this sympathetic drive would appear to be beneficial. The oral dopamine agonist Ibopamine causes vasodilation and reduces PNE levels at rest in patients with CHF.3 However, the influence of Ibopamine on peak oxygen consumption (VO2) and PNE levels during exercise in patients with CHF is unknown, and was investigated in this study

Ki Lie - One of the best experts on this subject based on the ideXlab platform.

  • ORAL Ibopamine SUBSTITUTION IN PATIENTS WITH INTRAVENOUS DOPAMINE DEPENDENCE
    1995
    Co-Authors: Girbes Arj, Dj Vanveldhuisen, Ar Milner, Bv Mccloskey, Jh Zwaveling, Jg Zijlstra, Ki Lie
    Abstract:

    In a prospective open study we evaluated whether intravenous dopamine infusions can be safely switched to enterally administered Ibopamine in dopamine-dependent patients. Six patients defined as being clinically stable, normovolaemic, but dopamine dependent, i.e. with repeated inability to stop intravenous dopamine, were included. Ibopamine was administered via a nasogastric or nasoduodenal tube. During the initial 48-hour period of Ibopamine administration the dopamine infusion was gradually decreased and then discontinued. Arterial blood pressure was continuously recorded via a 20-gauge cannula in the radial artery. Urine output was measured each hour. In all 6 patients it was possible to decrease and then discontinue the dopamine infusion whilst maintaining haemodynamic stability and an appropriate diuresis. It was then possible to discharge the patients from the intensive care unit. Normovolaemic, clinically stable but dopamine-dependent patients may be weaned off intravenous dopamine by substitution of enterally administered Ibopamine, allowing discharge from the intensive care unit

  • HEART-RATE-VARIABILITY IN PATIENTS WITH MILD-TO-MODERATE HEART-FAILURE - EFFECTS OF NEUROHORMONAL MODULATION BY DIGOXIN AND Ibopamine
    1995
    Co-Authors: Brouwer J, Boomsma F., Dj Vanveldhuisen, Dunselman Phjm, Haaksma J., Aj Manintveld, Ki Lie
    Abstract:

    Objectives. This study assessed the effects of digoxin and Ibopamine on variables of heart rate variability in relation to neurohormonal activation. Background. Analysis of heart rate variability can be used to study the autonomic dysfunction that characterizes chronic heart failure. In the Dutch Ibopamine Multicenter Trial, patients with heart failure were found to have increased neurohormonal activation with placebo therapy but not with digoxin and Ibopamine therapy. Methods. We studied 59 patients with mild to moderate heart failure (mean [+/-SEM] age 60 +/- 1 years, mean ejection fraction 0.30 +/- 0.01). Patients were randomized to double-blind treatment with digoxin (0.25 mg [n = 22]), Ibopamine (100 mg three times a day [n = 19]) or placebo (n = 18); background therapy consisted of furosemide (up to 80 mg). Results. After 3 months, plasma norepinephrine levels had increased with placebo, whereas they decreased with digoxin (+31 vs, -60 pg/ml, respectively, p 50 ms (pNN50) increased (+1.7 +/- 0.9%, p

  • EFFECT OF Ibopamine ON VENTRICULAR REMODELING AFTER EXPERIMENTAL MYOCARDIAL-INFARCTION - A COMPARISON WITH CAPTOPRIL
    1994
    Co-Authors: Wh Vangilst, Pa Degraeff, Fj Vanveldhuisen, Buikema H, Ki Lie
    Abstract:

    Remodeling after myocardial infarction (MI) is influenced not only by hemodynamic but possibly by neurohumoral factors as well. Ibopamine is an orally active dopamine agonist (DA) with both hemodynamic and neurohumoral properties in humans. The latter property prevails in rats. To study the dose-dependent effect of Ibopamine on myocardial remodeling and compare it with the effect of captopril, we randomized rats with (n = 27) or without (n = 27) experimental MI to captopril (25 mg/ kg/day), low-dose Ibopamine (10 mg/kg/day), high-dose Ibopamine (30 mg/kg/day), or no treatment. After 8-week treatment, hearts were isolated and left ventricular (LV) function, LV cavity volume, and infarct size (IS) were evaluated. Both Ibopamine and captopril significantly reduced plasma norepinephrine (NE) levels in rats with MI. was significantly reduced as compared with that of controls. IS was reduced in all three active treatment groups as compared with untreated rats. LV cavity volume was significantly increased in untreated rats with MI as compared with controls. This dilatation was attenuated by both Ibopamine and captopril. Ibopamine, comparable to captopril, administered early after coronary ligation reduced IS and subsequent ventricular dilatation, resulting in preservation of cardiac function in this rat model. This observation suggests a major role for neurohumoral activation in the process of remodeling

  • Double-Blind Placebo-Controlled Study of Ibopamine and Diagoxin in Patients With Mild to Moderate Heart Failure: Results of the Dutch of the Ibopamine Multicenter Trial (DIMT)
    'Elsevier BV', 1993
    Co-Authors: Dj ,van Veldhuisen, Dunselman Phjm, Aj ,man In 't Veld, Lok Dja, Dohmen Hjm, Jc Poortermans, Withagen Ajam, Wh Pasteunings, Brouwer J, Ki Lie
    Abstract:

    Objectives. This study was conducted to determine the efficacy and safety of long-term treatment with the orally active dopamine agonist Ibopamine in patients with mild to moderate chronic congestive heart failure and to compare the results with those of treatment with digoxin and placebo. Background. Ibopamine and digoxin are drugs that exert hemodynamic and neurohumoral effects. Because there is accumulating evidence that progression of disease in chronic heart failure is related not only to hemodynamic but also to neurohumoral factors, both drugs might be expected to have a favorable long-term effect. Methods. We studied 161 patients with mild to moderate chronic heart failure (80% in New York Heart Association functional class II and 20% in class In), who were treated with Ibopamine (n = 53), digoxin (n = 55) or placebo (n = 53) for 6 months. Background therapy consisted of furosemide (0 to 80 mg); all other drugs for heart failure were excluded. Clinical assessments were made at baseline and after 1, 3 and 6 months. Results. Of the 161 patients, 128 (80%) completed the study. Compared with placebo, digoxin but not Ibopamine significantly increased exercise time after 6 months (p = 0.008 by intention to treat analysis). Ibopamine was only effective in patients with relatively preserved left ventricular function, as it significantly increased exercise time in this subgroup (for patients with a left ventricular ejection fraction > 0.30; p = 0.018 vs, placebo). No patient receiving digoxin withdrew from the study because of progression of heart failure, compared with six patients receiving Ibopamine and two receiving placebo. At 6 months, plasma norepinephrine was decreased with digoxin and Ibopamine therapy (-106 and -13 pg/ml, respectively) but increased with placebo administration (+62 pg/ml) (both p

  • ENDOTHELIUM-DEPENDENT RELAXATION IN 2 DIFFERENT MODELS OF CHRONIC HEART-FAILURE AND THE EFFECT OF Ibopamine
    1993
    Co-Authors: Buikema H, Dj Vanveldhuisen, Ki Lie, Wh Vangilst, Desmet Bjgl, Wesseling H
    Abstract:

    Objectives: The purpose was to relate endothelium dependent relaxation to neurohumoral and haemodynamic changes in rats with chronic heart failure. Methods: Rats were submitted to either coronary ligation causing myocardial infarction or banding of the abdominal aorta (aortic stenosis), and comparisons were made with normal rats (n=20 per group). Starting six weeks after surgery, half of the experimental animals received Ibopamine and the other half served as controls and were given saline for another three weeks. After this, haemodynamic and neurohumoral variables were determined and the rats were killed. Rings of both the thoracic and abdominal aorta were studied in organ baths to measure their response to vasoactive agents. Results: Increased plasma noradrenaline concentrations in rats with myocardial infarction and aortic stenosis were reduced by Ibopamine. Blood pressure and heart rate, which were higher in rats with aortic stenosis than in rats with myocardial infarction and in normal rats, were unaffected by Ibopamine. The maximal relaxation to sodium nitrite was depressed in the thoracic aorta from rats with myocardial infarction. The pIC(50) of metacholine induced relaxation was smaller in the thoracic aorta from rats with myocardial infarction and aortic stenosis. By contrast, both pIC(50) and the maximal relaxation (Emax) were increased in the abdominal aorta from rats with aortic stenosis, whereas Emax was smaller in rats with myocardial infarction. Ibopamine had no significant effects on these responses. Conclusions: Endothelium dependent relaxation to metacholine was selectively altered in rats with chronic heart failure due to aortic stenosis, probably because of differences in regional haemodynamics. In rats with myocardial infarction, however, endothelium dependent relaxation was impaired in both the thoracic and abdominal aorta. Ibopamine acted as a neurohumoral modulator by reducing increased noradrenaline concentrations but had no significant effect on either endothelium dependent or independent relaxation

De Gregorio F - One of the best experts on this subject based on the ideXlab platform.

Van Veldhuisen, Dirk J. - One of the best experts on this subject based on the ideXlab platform.

  • Heart rate variability in patients with mild to moderate heart failure: Effects of neurohormonal modulation by digoxin and Ibopamine
    American College of Cardiology. Published by Elsevier Inc., 1995
    Co-Authors: Brouwer Jan, Van Veldhuisen, Dirk J., Boomsma Frans, Haaksma Jaap, Man In 't Veld, Arie J., Dunselman, Peter H.j.m., Lie K.i.
    Abstract:

    Objectives.This study assessed the effects of digoxin and Ibopamine on variables of heart rate variability in relation to neurohormonal activation.Background.Analysis of heart rate variability can be used to study the autonomic dysfunction that characterizes chronic heart failure. In the Dutch Ibopamine Multicenter Trial, patients with heart failure were found to have increased neurohormonal activation with placebo therapy but not with digoxin and Ibopamine therapy.Methods.We studied 59 patients with mild to moderate heart failure (mean [±SEM]age 60 ± 1 years, mean ejection fraction 0.30 ± 0.01). Patients were randomized to double-blind treatment with digoxin (0.25 mg [n = 22]), Ibopamine (100 mg three times a day [n = 19]) or placebo (n = 18); background therapy consisted of furosemide (up to 80 mg).Results.After 3 months, plasma norepinephrine levels had increased with placebo, whereas they decreased with digoxin (+31 vs. −60 pg/ml, respectively, p < 0.01). With Ibopamine, a nonsig nificant decrease was observed (−27 pg/ml, p = 0.10). All variables of heart rate variability showed a deterioration in the placebo group. With digoxin, the percent differences between successive RR intervals >50 ms (pNN50) increased (+ 1.7 ± 0.9%, p < 0.01), along with absolute and normalized high frequency power (+40 ± 33 ms2, p < 0.05 and +2.4 ± 1.7%, p < 0.01, respectively). These changes were observed during daytime hours only and were most pronounced in patients with the most impaired baseline heart rate variability. With Ibopamine, nonsignificant trends similar to the changes with digoxin were observed.Conclusions.In patients with early stages of heart failure, digoxin may prevent a progressive deterioration in heart rate variability, whereas Ibopamine does not show statistically significant effects. The changes in heart rate variability with digoxin parallel an observed decrease in neurohormonal activation. Digoxin apparently enhances cardiac vagal tone in the setting of neuroendocrine activation

  • 1031-35 Value of Ibopamine as Adjunct to Maximal Oral Medication in Patients with Moderately Severe Congestive Heart Failure; a Double-Blind, Placebo-controlled Study
    American College of Cardiology. Published by Elsevier Inc., 1995
    Co-Authors: Szabó, Balázs M., Van Veldhuisen, Dirk J., Van Der Burgh, Pieter H., Kruik Joost, Lie K.i.
    Abstract:

    Multiple drug therapy, including ACE inhibitors, diuretics, vasodilators and digoxin is currently used to reduce signs and symptoms of chronic heart failure (CHF). Optimal treatment of these patients (pts) is a major clinical problem, as the prevalence of CHF increases. Ibopamine, a novel oral dopamine agonist with peripheral vasodilating and neurohumoral inhibiting effects, may have additive value in the treatment of pts with moderately severe CHF, already treated with ACE-inhibitors.To evaluate the additive value of Ibopamine as adjunctive to maximal CHF treatment we studied 60 pts with NYHA class III-IV CHF, who were assigned to treatment with Ibopamine (3 dd 100mg) or placebo in a double-blind, randomized fashion.We examined the effect of Ibopamine on peak oxygen consumption (VO2), neurohumoral factors and cardiac arrhythmias during 48 hrs ECG monitoring. Neurohumoral parameters were determined at rest and during exercise and included serum norepinephrine, epinephrine, aldosterone and plasma renin activity. All assessments were made at baseline and after 12 weeks of study treatment.Baseline dataOf the 60 pts, 40 pts (67%) had ischemic heart disease andlor old myocardial infarction, and 20 (33%) non-ischemic heart disease (16 pts (27%) dilated myocardiopathy). Mean age was 63±10 years, left ventricular ejection fraction 0.23±0.08, peak VO2 15.0±2.4 ml/min/kg and 44 of the patients (73%) were male. Background CHF therapy included ACE-inhibitors (100%), diuretics (100%), and digoxin, nitrates, amiodarone when required. At baseline resting serum norepinephrine was 724±78pg/ml, epinephrine 68±17pg/ml, aldosterone 0.50±0.08nmol/l and plasma renin activity 5.7±0.9ng/ml/hr.ResultsThe study was recently completed, the study data are currently analyzed and the results will be presented at the meeting

  • Renal and systemic hemodynamic effects of Ibopamine in patients with mild to moderate congestive heart failure
    'Ovid Technologies (Wolters Kluwer Health)', 1995
    Co-Authors: Lieverse, Alouisius G., Van Veldhuisen, Dirk J., Smit, Andries J., Zijlstra, Jan G., Meijer Sytze, Reitsma, Wepco D., Lie Kong, Girbes, Armand R.j.
    Abstract:

    To study the hemodynamic and renal effects of the orally (p. o.) active dopamine (DA) agonist Ibopamine, we examined 10 patients with mild to moderate congestive heart failure (CHF). who were stable while treated with digoxin and diuretics. All patients were in New York Heart Association (NYHA) functional class II-III; their mean age was 63 years (range 51-79 years), and mean left ventricular ejection fraction (LVEF) was 28% (range 18-360%). The protocol consisted of a control study-day with measurements of renal characteristics including glomerular filtration rate (GFR). effective renal plasma How (ERPF), and filtration fraction (FF). One-week later, systemic and renal hemodynamics were measured simultaneously before and after patients received one 100-mg tablet of Ibopamine. Ibopamine caused a slight but significant increase in both FRPF (from 288 ± 32 ml/min/1.73 m 2 at baseline to 316 ± 32 ml/min/1.73 m 2 after Ibopamine) and GFR (from 77 ± 8 to 85 ± 8 ml/min/1.73 m 2 ; both p < 0.05); FF was not affected (mean value 0.26 ± 0.02). Sodium excretion was not influenced by Ibopamine. but diuresis increased significantly. Cardiac output (CO) increased significantly (from 4.0 ± 0.4 L/min at baseline to a maximum of 5.0 L/min after Ibopamine, p < 0.05). mainly due to decreased systemic vascular resistance (SVR). Heart rate (HR) and blood pressure (BP) were unchanged throughout the studies. The percentage of contribution of CO to renal blood flow (RBF) was not significantly affected by Ibopamine. In conclusion, Ibopamine causes a slight but significant increase in both ERPF and GFR and a significant increase in diuresis, but no increase in sodium excretion in patients with mild to moderate CHF. In addition, the drug increases CO and decreases SVR to a similar extent. Therefore, the renal effects of Ibopamine with equal pre- and postglomerular vasodilation, appear to be primarily due to its systemic hemodynamic effects

  • Neurohumoral and hemodynamic effects of Ibopamine in a rat model of chronic myocardial infarction and heart failure
    'Springer Science and Business Media LLC', 1994
    Co-Authors: Van Veldhuisen, Dirk J., Girbes, Armand R.j., De Graeff, Pieter A., Van Gilst, Wiek H., De Smet, Bart J.g.l., Scholtens Egbert, Buikema Hendrik, Wesseling Harry, Lie K.
    Abstract:

    There is increasing evidence that both neurohumoral and hemodynamic factors play a role in disease progression in chronic heart failure (CHF). To examine the influence of the oral dopamine agonist Ibopamine on these factors, we studied 20 rats with chronic myocardial infarction and CHF, and compared them with 20 normal rats. After 6 weeks, rats were randomly divided between control treatment (50%) or Ibopamine (50%) for 3 weeks. At the end of the study, plasma and tissue neurohumoral parameters, as well as hemodynamics, were determined. In infarcted rats, the elevated plasma norepinephrine (PNE) levels were reduced by Ibopamine (251±19 vs. 138±32 pg/ml; p

  • Double-Blind Placebo-Controlled Study of Ibopamine and Diagoxin in Patients With Mild to Moderate Heart Failure: Results of the Dutch of the Ibopamine Multicenter Trial (DIMT)
    Published by Elsevier Inc., 1993
    Co-Authors: Van Veldhuisen, Dirk J., Brouwer Jan, Man In 't Veld, Arie J., Dunselman, Peter H.j.m., Lok, Dirk J.a., Dohmen, Henk J.m., Poortermans J.cees, Withagen, Adrie J.a.m., Pasteuning W.hans, Lie K.i.
    Abstract:

    AbstractObjectives. This study was conducted to determine the efficacy and safety of long-term treatment with the orally active dopamine agonist Ibopamine in patients with mild to moderate chronic congestive heart failure and to compare the results with those of treatment with digoxin and placebo.BackgroundIbopamine and digoxin are drugs that exert hemodynamic and neurohumoral effects. Because there is accumulating evidence that progression of disease in chronic heart failure is related not only to hemodynamic but also to neurohumoral factors, both drugs might be expected to have a favorable long-term effect.Methods. We studied 161 patients with mild to moderate chronic heart failure (80% in New York Heart Association functional class II and 20% in class III), who were treated with Ibopamine (n = 53), digoxin (n = 55) or placebo (n = 53) for 6 months. Background therapy consisted of furosemide (0 to 80 mg); all other drugs for heart failure were excluded. Clinical assessments were made at baseline and after 1, 3 and 6 months.Results. Of the 161 patients, 128 (80%) completed the study. Compred with placebo, digoxin but not Ibopamine significantly increased exercise time after 6 months (p = 0.008 by intention to treat analysis). Ibopamine was only effective in patients with relatively preserved left ventricular function, as it significantly increased exercise time in this subgroup (for patients with a left ventricular ejection fraction > 0.30; p = 0.018 vs. placebo). No patient receiving digoxin withdrew from the study because of progression of heart failure, compared with six patients receiving Ibopamine and two receiving placebo. At 6 months, plasma norepinephrine was decreased with digoxin and Ibopamine therapy (−106 and −13 pg/ml, respectively) but increased with placebo administration (+62 pg/ml) (both p < 0.05 vs. placebo). Plasma aldosterone was unaffected, but renin was decreased by boat agents after 6 months (p < 0.05 vs. placbo). Total mortality and ambulatory arrhythmias were not significantly affected by the two drugs.Conclusions. Ibopamine and digoxin both inhibit neurohumoral activation in patients with mild to moderate chronic heart failure. However, the clinical effects of these drugs are different and appear to be related to the degree of left ventricular dysfunction

Related terms

Ibopamine - 15 days free trial to Access Experts & Abstracts